Pacritinib Effectiveness in Real-world Settings
ConditionMyelofibrosis (MF)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSwedish Orphan Biovitrum
About this trial
This study aims to evaluate real-world treatment patterns and effectiveness of pacritinib, including hematologic and clinical outcomes, and survival through a site-based retrospective chart review of medical records of patients with MF.
Eligibility criteria
Qualifiers
Adult patients must be ≥18 years of age at the index date
Patients diagnosed with MF with platelet counts ≥50 x 109/L at the time of treatment initiation with pacritinib. If multiple values are available within 30 days prior to initiating treatment with pacritinib will use the value closest to index date
Patients will be required to have ≥1 month of treatment with pacritinib and ≥6 months of observation from the start of pacritinib unless the patient died within 6 months of starting pacritinib
If peripheral blasts were evaluated prior to index, they must be <10%. If not evaluated, patients will be included unless a healthcare provider has indicated in the medical record that there is a concern that the patient has transitioned to accelerated/blast phase disease at or prior to index
Disqualifiers
Diagnosis of acute myeloid leukemia prior to index
Physician-concern that the patient has transitioned to accelerated/blast phase disease if peripheral blasts were not evaluated
Treated with 2 or more JAK inhibitors prior to initiating treatment with pacritinib
Treated with pacritinib in a clinical trial setting
Trial design
Treatments tested in this trial
- Not applicable- observational study
Treatment groups
No treatment groups listed
Locations
Sponsors and collaborators
Swedish Orphan Biovitrum
Lead sponsor
IQVIA RDS Inc.
Collaborator
Source ClinicalTrials.gov